![Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease - Kriván - Vox Sanguinis - Wiley Online Library Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease - Kriván - Vox Sanguinis - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ff1349b6-a96f-4942-81f0-cc162dd384f5/vox.v117.9.cover.jpg?trick=1663330965618)
Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease - Kriván - Vox Sanguinis - Wiley Online Library
Overview of comments received on the guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg
![PDF) Safety monitoring of the intravenous immunoglobulin preparation Intratect (R) in primary and secondary immunodeficiencies: a prospective non-interventional study PDF) Safety monitoring of the intravenous immunoglobulin preparation Intratect (R) in primary and secondary immunodeficiencies: a prospective non-interventional study](https://www.researchgate.net/profile/Artur-Bauhofer/publication/267743705/figure/tbl1/AS:613448727658531@1523268982507/Adverse-events-n_Q320.jpg)
PDF) Safety monitoring of the intravenous immunoglobulin preparation Intratect (R) in primary and secondary immunodeficiencies: a prospective non-interventional study
![Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (LIPS): study protocol for a randomized controlled trial. - Abstract - Europe PMC Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (LIPS): study protocol for a randomized controlled trial. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4226877/bin/13063_2013_2280_Fig1_HTML.jpg)
Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (LIPS): study protocol for a randomized controlled trial. - Abstract - Europe PMC
VI.2 Elements for a Public Summary Intratect 50 g/l and Intratect 100 g/l are solutions for intravenous infusion (infusion into
INTRATECT 50 g/l 1. NAME OF THE MEDICINAL PRODUCT Intratect 50 g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOS
![PDF) Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome: A Randomized Trial. Annals of Internal Medicine, 2017; 167:476-83. PDF) Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome: A Randomized Trial. Annals of Internal Medicine, 2017; 167:476-83.](https://www.researchgate.net/profile/Mark-Sanders-5/publication/320244357/figure/fig1/AS:614020700721182@1523405351774/figure-fig1_Q320.jpg)
PDF) Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome: A Randomized Trial. Annals of Internal Medicine, 2017; 167:476-83.
![Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use | SpringerLink Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.2165%2F11537660-000000000-00000/MediaObjects/40259_2012_24040211_Tab1.jpg)
Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use | SpringerLink
![Diagram of mean group values for cumulative dose of ozone (micrograms)... | Download Scientific Diagram Diagram of mean group values for cumulative dose of ozone (micrograms)... | Download Scientific Diagram](https://www.researchgate.net/publication/24432814/figure/fig1/AS:453753997402113@1485194791457/Diagram-of-mean-group-values-for-cumulative-dose-of-ozone-micrograms-against-time-of.png)